Protalix BioTherapeutics, Inc. (PLX)

Market Cap	180.59M
Revenue (ttm)	61.95M
Net Income (ttm)	6.28M
Shares Out	79.73M
EPS (ttm)	0.08
PE Ratio	29.05
Forward PE	9.57
Dividend	n/a
Ex-Dividend Date	n/a

Volume	331,881
Open	2.360
Previous Close	2.380
Day's Range	2.240 - 2.380
52-Week Range	1.160 - 3.100
Beta	-0.27
Analysts	Strong Buy
Price Target	15.00 (+562.25%)
Earnings Date	Nov 13, 2025

About PLX

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell e...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 15, 1998
• Employees: 213
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: PLX
• Website: https://www.protalix.com

Financial Performance

In 2024, Protalix BioTherapeutics's revenue was $53.40 million, a decrease of -18.47% compared to the previous year's $65.49 million. Earnings were $2.93 million, a decrease of -64.73%.

Analyst Summary

According to one analyst, the rating for PLX stock is "Strong Buy" and the 12-month stock price target is $15.0.

Price Target

$15.0

(562.25% upside)

Analyst Consensus: Strong Buy